Daily Derm Times: April 23, 2025

Author(s):

Emma Andrus, Editor

Key Takeaways

A dual-energy approach enhances skin hydration by promoting endogenous hyaluronic acid synthesis, offering a novel alternative to traditional fillers.
Regenerative aesthetics, including growth factor skincare, show promising potential for future dermatologic advancements.
Biologic therapies for bullous pemphigoid achieve high remission rates, with dupilumab and omalizumab showing significant efficacy.
Chronic hand eczema involves complex immune mechanisms, significantly impacting patients physically and emotionally.
Promising phase 3 trial results for Qtorin 3.9% rapamycin gel in treating microcystic lymphatic malformations are discussed.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Journal Digest: April 23

This review of the latest dermatologic studies includes insights into epidermolysis bullosa for primary care providers, patient-reported impact of atopic dermatitis on pediatric and adolescent patients, and more.

Dual-Energy Approach Boosts Skin Hydration

Unlike traditional fillers, this method rejuvenates skin structure by promoting endogenous HA synthesis.

What Dermatologists Need to Know About the Future of Regenerative Aesthetics

While products like growth factor skincare already have demonstrated benefits, this is only the beginning, according to Prithwiraj Maitra, PhD.

New Insights into Biologic Therapies for BP

Complete remission was achieved in over 87% of dupilumab users and 64% of omalizumab users.

Understanding Chronic Hand Eczema: Cellular Mechanisms and Therapeutic Implications

Omar Noor, MD, FAAD, explores the complex immune and cellular mechanisms behind CHE and highlights its significant physical and emotional toll on patients.

JAK Inhibitors as Flexible, Fast-Acting Option for Refractory AD

Raj Chovatiya, MD, PhD, MSCI, provides insights on the clinical advantages of JAK inhibitors for atopic dermatitis.

Amy Paller, MD, MS, Discusses Phase 3 Trial Results for Qtorin 3.9% Rapamycin Gel

Paller discusses the promising phase 3 trial SELVA trial results for Qtorin 3.9% rapamycin gel, an investigative treatment for microcystic lymphatic malformations.

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!